Data / Drug companies / Azurity Pharmaceuticals, Inc.
Azurity Pharmaceuticals, Inc.: 56 products in the FDA NDC directory, labeler code 24338
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Azurity Pharmaceuticals, Inc. (labeler code 24338) lists 56 products in the FDA National Drug Code Directory, covering 23 finished drugs by generic name. By type: 54 prescription drugs, 2 over the counter drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on August 11, 2026.
The request: Watch Azurity Pharmaceuticals, Inc. (FDA labeler code 24338): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 24338
- Products in commercial distribution
- 56
- Packages
- 64
- Finished drugs by generic name
- 23
- Prescription products
- 54
- Over the counter products
- 2
- Controlled substance products
- Schedule II 14, Schedule III 2
- Flagged as original packager
- 55 of 55 products that carry the flag
- Started marketing in the last 12 months
- 11
- Earliest marketing start
- April 18, 2011
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 38 | 67.9% |
| Generic drugs (ANDA) | 18 | 32.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 54 | 96.4% |
| Over the counter drugs | 2 | 3.6% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Dextroamphetamine sulfate | 7 | 17 |
| Erythromycin ethylsuccinate | 6 | 8 |
| Erythromycin | 6 | 36 |
| Lisdexamfetamine dimesylate oral | 5 | 1 |
| Telmisartan, amlodipine and indapamide | 3 | 1 |
| Lomustine | 3 | 4 |
| Testosterone cypionate | 2 | 24 |
| Nilotinib | 2 | 10 |
| Nimodipine | 2 | 4 |
| Ferumoxytol | 2 | 3 |
| Sodium sulfate, potassium sulfate, magnesium sulfate | 2 | 6 |
| Ivermectin | 2 | 33 |
| Amphetamine sulfate | 2 | 12 |
| Hydralazine hydrochloride and isosorbide dinitrate | 1 | 3 |
| Clonidine hydrochloride oral | 1 | 1 |
| Bendamustine hydrochloride | 1 | 10 |
| Sodium sulfate, magnesium sulfate, and potassium chloride | 1 | 2 |
| Sitagliptin hydrochloride oral | 1 | 1 |
| Carmustine | 1 | 13 |
| Mycophenolate mofetil | 1 | 37 |
| Sotalol hydrochloride | 1 | 25 |
| Triptorelin | 1 | 1 |
| Meloxicam | 1 | 54 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 17 | 30.4% |
| Solution | 10 | 17.9% |
| Injection | 4 | 7.1% |
| Tablet, film coated | 3 | 5.4% |
| Suspension | 3 | 5.4% |
| Tablet, delayed release | 3 | 5.4% |
| Capsule, gelatin coated | 3 | 5.4% |
| Injection, solution | 2 | 3.6% |
| Granule, for suspension | 2 | 3.6% |
| Solution, concentrate | 2 | 3.6% |
| Lotion | 2 | 3.6% |
| Kit | 2 | 3.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Ivermectin | 24338-119 | Lotion | Generic drugs (ANDA) | August 11, 2026 |
| GoLYTELY | 24338-236 | Powder, for solution | New drug applications (NDA) | April 17, 2026 |
| Suflave | 24338-550 | Kit | New drug applications (NDA) | April 1, 2026 |
| Sutab | 24338-201 | Tablet | New drug applications (NDA) | April 1, 2026 |
| SUPREP Bowel Prep | 24338-177 | Solution, concentrate | New drug applications (NDA) | April 1, 2026 |
| SUPREP Bowel Prep | 24338-175 | Solution, concentrate | New drug applications (NDA) | April 1, 2026 |
| Arynta | 24338-162 | Solution | New drug applications (NDA) | March 20, 2026 |
| Arynta | 24338-160 | Solution | New drug applications (NDA) | March 20, 2026 |
| Arynta | 24338-109 | Solution | New drug applications (NDA) | March 20, 2026 |
| Arynta | 24338-103 | Solution | New drug applications (NDA) | March 20, 2026 |
| Arynta | 24338-019 | Solution | New drug applications (NDA) | March 20, 2026 |
| Gleostine | 24338-342 | Capsule, gelatin coated | New drug applications (NDA) | October 24, 2025 |
| Gleostine | 24338-341 | Capsule, gelatin coated | New drug applications (NDA) | October 24, 2025 |
| Gleostine | 24338-340 | Capsule, gelatin coated | New drug applications (NDA) | October 24, 2025 |
| Javadin | 24338-115 | Solution | New drug applications (NDA) | October 23, 2025 |
| FeraBright | 24338-510 | Injection | New drug applications (NDA) | October 20, 2025 |
| FeraBright | 24338-310 | Injection | New drug applications (NDA) | October 20, 2025 |
| Widaplik | 24338-003 | Tablet | New drug applications (NDA) | October 20, 2025 |
| Widaplik | 24338-002 | Tablet | New drug applications (NDA) | October 20, 2025 |
| Widaplik | 24338-001 | Tablet | New drug applications (NDA) | October 20, 2025 |
| Xifyrm | 24338-153 | Injection | New drug applications (NDA) | June 5, 2025 |
| Vivimusta | 24338-270 | Injection | New drug applications (NDA) | April 1, 2025 |
| Brynovin | 24338-017 | Solution | New drug applications (NDA) | April 1, 2025 |
| Danziten | 24338-155 | Tablet | New drug applications (NDA) | November 30, 2024 |
| Danziten | 24338-154 | Tablet | New drug applications (NDA) | November 30, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.